Show simple item record

dc.creatorPaniri, Alireza
dc.creatorAkhavan-Niaki, Haleh
dc.date.accessioned2020-08-11T14:16:34Z
dc.date.available2020-08-11T14:16:34Z
dc.date.created2020
dc.identifier.issn0024-3205spa
dc.identifier.otherhttps://doi.org/10.1016/j.lfs.2020.118114spa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/11824
dc.description.abstractThe world has witnessed a high morbidity and mortality caused by SARS-CoV-2, and global death toll is still rising. Exaggerated inflammatory responses are thought to be more responsible for infiltrated immune cells accumulation, organ damage especially lung, dyspnea, and respiratory failure rather than direct effect of viral replication. IL-6 and NLRP3 inflammasome are the major immune components in immune responses stimulation upon pathogen infection. It's noteworthy that the function and expression of these components are remarkably influenced by non-coding RNAs including long non-coding RNAs. Given the potential role of these components in organ damage and pathological manifestations of patients infected with COVID-19, their blockage might be a hopeful and promising treatment strategy. Notably, more study on long non-coding RNAs involved in inflammatory responses could elevate the efficacy of anti-inflammatory therapy. In this review we discuss the potential impact of IL-6 and NLRP3 inflammasome blocker drugs on inflammatory responses, viral clearance, and pathological and clinical manifestations. Collectively, anti-inflammatory strategy might pave the way to diminish clinical and pathological manifestations and thereby discharging patients infected with COVID-19 from hospital.spa
dc.format.extent13 páginasspa
dc.format.mimetypeimage/jepgspa
dc.publisherLife Sciencesspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectSARS-CoV-2spa
dc.subjectCOVID-19spa
dc.subjectInflammationspa
dc.subjectCytokine release syndromespa
dc.subjectInflammasomespa
dc.subjectDrugspa
dc.titleEmerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: Role of lncRNAs in cytokine storm modulationspa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/embargoedAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.rights.localAcceso restringidospa
dc.identifier.doihttps://doi.org/10.1016/j.lfs.2020.118114spa


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record